Elevation of urinary liver-type fatty acid binding protein after cardiac catheterization related to cardiovascular events

被引:5
|
作者
Kamijo-Ikemori, Atsuko [1 ,3 ]
Hashimoto, Nobuyuki [2 ]
Sugaya, Takeshi [1 ]
Matsui, Katsuomi [1 ]
Hisamichi, Mikako [1 ]
Shibagaki, Yugo [1 ]
Miyake, Fumihiko [2 ]
Kimura, Kenjiro [1 ]
机构
[1] St Marianna Univ Sch Med, Dept Hypertens & Nephrol, Kawasaki, Kanagawa, Japan
[2] St Marianna Univ Sch Med, Dept Cardiol, Kawasaki, Kanagawa, Japan
[3] St Marianna Univ Sch Med, Dept Anat, Kawasaki, Kanagawa, Japan
来源
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE | 2015年 / 8卷
关键词
chronic kidney disease; urinary liver-type fatty acid binding protein; L-FABP; contrast medium; urinary biomarker; cardiovascular event; renal dysfunction;
D O I
10.2147/IJNRD.S88467
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Contrast medium (CM) induces tubular hypoxia via endothelial damage due to direct cytotoxicity or viscosity. Urinary liver-type fatty acid binding protein (L-FABP) increases along with tubular hypoxia and may be a detector of systemic circulation injury. The aim of this study was to evaluate the clinical usefulness of detecting increases in urinary L-FABP levels due to administration of CM, as a prognostic biomarker for cardiovascular disease in patients without occurrence of CM-induced nephropathy undergoing cardiac catheterization procedure (CCP). Methods: Retrospective longitudinal analyses of the relationship between urinary L-FABP levels and occurrence of cardiovascular events were performed (n=29). Urinary L-FABP was measured by ELISA before CCP, and at 6, 12, 24, and 48 hours after CCP. Results: Urinary L-FABP levels were significantly higher at 12 hours (P<0.05) and 24 hours (P<0.005) after CCP compared with before CCP, only in the patients with occurrence of cardiovascular events (n=17), but not in those without cardiovascular events (n=12). The parameter with the largest area under the curve (0.816) for predicting the occurrence of cardiovascular events was the change in urinary L-FABP at 24 hours after CCP. The difference in urinary L-FABP levels (.L-FABP >11.0 mu g/g creatinine) between before CCP and at 24 hours after CCP was a risk factor for the occurrence of cardiovascular events (hazard ratio, 4.93; 95% confidence interval, 1.27-19.13; P=0.021). Conclusion: Measurement of urinary L-FABP before CCP and at 24 hours after CCP in patients with mild to moderate renal dysfunction may be an important indicator for risk stratification of onset of cardiovascular events.
引用
收藏
页码:91 / 99
页数:9
相关论文
共 50 条
  • [1] Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease
    Atsuko Kamijo
    Takeshi Sugaya
    Akihisa Hikawa
    Masaya Yamanouchi
    Yasunobu Hirata
    Toshihiko Ishimitsu
    Atsushi Numabe
    Masao Takagi
    Hiroshi Hayakawa
    Fumiko Tabei
    Tokuichiro Sugimoto
    Naofumi Mise
    Masao Omata
    Kenjiro Kimura
    Molecular and Cellular Biochemistry, 2006, 284 : 175 - 182
  • [2] Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease
    Kamijo, Atsuko
    Sugaya, Takeshi
    Hikawa, Akihisa
    Yamanouchi, Masaya
    Hirata, Yasunobu
    Ishimitsu, Toshihiko
    Numabe, Atsushi
    Takagi, Masao
    Hayakawa, Hiroshi
    Tabei, Fumiko
    Sugimoto, Tokuichiro
    Mise, Naofumi
    Omata, Masao
    Kimura, Kenjiro
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2006, 284 (1-2) : 175 - 182
  • [3] Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis
    Zhang, Li
    Xue, Shuai
    Wu, Meiyan
    Dong, Dan
    FRONTIERS IN MEDICINE, 2022, 9
  • [4] The Urinary Level of Liver-type Fatty Acid Binding Protein in Children with Febrile UTI
    Rafiei, Alireza
    Arzefuni, Fatemeh Abedi
    Mohammadjafari, Hamid
    Yazdani-Charati, Jamshid
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2020, 14 (03) : 191 - 197
  • [5] Urinary Liver-Type Fatty Acid Binding Protein, a Biomarker for Disease Progression, Dialysis and Overall Mortality in Chronic Kidney Disease
    Mitsides, Nicos
    Mitra, Vikram
    Saha, Ananya
    Harris, Shelly
    Kalra, Philip A.
    Mitra, Sandip
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (10):
  • [6] Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis
    Sato E.
    Kamijo-Ikemori A.
    Oikawa T.
    Okuda A.
    Sugaya T.
    Kimura K.
    Nakamura T.
    Shibagaki Y.
    Renal Replacement Therapy, 3 (1)
  • [7] Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs
    Takashima, Satoshi
    Nagamori, Yumiko
    Ohata, Keiichi
    Oikawa, Tsuyoshi
    Sugaya, Takeshi
    Kobatake, Yui
    Nishii, Naohito
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2021, 83 (09): : 1465 - 1471
  • [8] Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD
    Matsui, Katsuomi
    Kamijo-Ikemori, Atsuko
    Imai, Naohiko
    Sugaya, Takeshi
    Yasuda, Takashi
    Tatsunami, Shinobu
    Toyama, Tadashi
    Shimizu, Miho
    Furuichi, Kengo
    Wada, Takashi
    Shibagaki, Yugo
    Kimura, Kenjiro
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (02) : 195 - 203
  • [9] Urinary liver-type fatty acid-binding protein in pediatric nephrotic syndrome and tubular dysfunction
    Nishida, Masashi
    Kawakatsu, Hidekazu
    Hamaoka, Kenji
    PEDIATRICS INTERNATIONAL, 2018, 60 (05) : 442 - 445
  • [10] Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease
    Nakamura, Tsukasa
    Sugaya, Takeshi
    Kawagoe, Yasuhiro
    Suzuki, Tsukasa
    Ueda, Yoshihiko
    Koide, Hikaru
    Inoue, Teruo
    Node, Koichi
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2007, 333 (06): : 321 - 326